Focus on Equities that offer Growth,
Value and Strong Potential Return
Monday, November 30, 2015
AcelRx Pharmaceuticals, Inc.
In-Depth Research Report Available for ACRX
Not a Member?
No problem! Take a moment to
activate your FREE account here:
Company Profile ACRX
On September 22, 2015, AcelRx announced that the European Commission (EC) approved Zalviso™ (sufentanil sublingual tablet system) for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting.
Going forward ... (see research report)